Our Stem Cell Clinic

Okyanos Heart Institute Stem Cell Clinic

The name Okyanos (Oh-key-AH-nos), the Greek god of the river Okeanos, symbolizes the primary mechanism of action that adult stem cells can provide your heart—the improvement of blood flow in tissue which has insufficient blood flow (a condition medically known as ischemia.)

You may be one of approximately 2.2 million patients with coronary artery disease in the United States alone who would not likely benefit from additional stents, bypass procedures or medications. You may also be living with heart damage, whether caused by a heart attack or severe blockages in the arteries.

At Okyanos, our mission is to bring a new standard of care and a better quality of life to patients with coronary artery disease (CAD), a heart disease, using cardiac stem cell therapy.

Why The Bahamas?

Our facility, built to and operated in accordance with applicable U.S. Surgical Center accreditation standards, is located in downtown Freeport on Grand Bahama Island. Our medical team is comprised of highly trained medical staff, and is led by a team of US-licensed medical professionals, cardiologists and cell therapy experts.

The commitment of the Bahamian government to the provision of world-class medical care has helped enable us to deliver this new coronary artery disease treatment option to our patients traveling from around the world to our state-of-the-art cardiac catheterization lab in Freeport.

Your Cardiac Stem Cell Treatment

Okyanos Heart Institute Patient RoomOkyanos uses adult stem cells sourced from your own adipose (fat) tissue. We encourage you to become educated on all the steps involved with undergoing cardiac cell therapy; however, a summary of the treatment is listed here:

  1. First, a routine liposuction procedure obtains a small amount of adipose (fat) tissue.
  2. Adult stem cells are isolated from your fat using the EU-approved Celution® System.
  3. The cells are then injected directly into or around damaged zones of the heart via a catheter.
  4. The patient recovers and is observed by our doctors and nursing staff for 4-6 hours after the procedure.

How Okyanos Cardiac Cell Therapy Can Help You

One of the ways heart tissue can become damaged is as a result of plaque deposits in the coronary arteries. These deposits block blood flow to the heart muscle that can lead to damage. Stem cells derived from a person’s own adipose (fat) tissue and delivered to a weakened heart can stimulate the growth of new blood vessels, a process known as angiogenesis.

As demonstrated in the clinical trial known as “PRECISE,” some of the restorative benefits of the treatment include:

  • Improved blood flow in the heart
  • Enhanced intake and use of oxygen
  • Improvement in the ability to perform physical activity

In addition to PRECISE, a number of other cardiac cell therapy trials done at leading research institutions such as Texas Heart Institute, University of Miami and Minnesota Heart Institute have shown results that stem cell therapy can have a positive, measurable and persistent effect on the heart.

Heart Disease Treatment: Our Focus is You

Okyanos Heart Institute Reception AreaCo-founder and CEO of Okyanos Matt Feshbach explains our focus simply. “Okyanos was founded to bring a new option, backed by strong science and rigorous clinical trials, to CAD patients who have exhausted all other options. Maximizing the quality of life for heart disease patients, their families and our society is the singular focus of Okyanos.”

To learn more, you may contact a Patient Liaison by requesting a free educational consultation or dialing 855.OKYANOS (659.2667).


Theoi Project. Okeanos.

Cytori Therapeutics (2010) Adipose-Derived Regenerative Cells Improve Cardiac Functional Capacity at 18 Months in Chronic Ischemic Heart Disease Patients; Statistically Significant Improvement in MVO2 Reported by Cytori at American Heart Association.

Perin et al (2014) Adipose-Derived Regenerative Cells in Patients with Ischemic Cardiomyopathy: The PRECISE Trial, American Heart Journal, Vol. 168, Number 1.